Cowlpane has published 9 articles on biotech — primarily in Markets, Tech, Economy , with coverage from 2026. Sourced from global financial publications.
A $5.5 billion blow to short sellers marks a violent reversal for Moderna as cancer vaccine data shifts the biotech narrative.
Moderna's experimental mRNA success shifts the biotech landscape from broad treatments to highly targeted cancer therapies.
Small-cap firms bioAffinity and Algo Grande are tapping private capital to fund critical expansion, shifting their risk-reward profiles for retail investors.
Moderna and Merck's personalized mRNA melanoma vaccine proves efficacy in Phase 3 trials, threatening the dominance of traditional oncology regimens.
Researchers apply photosynthetic processes to treat dry eye, potentially disrupting the multi-billion dollar ophthalmic drug market.
New executive orders threaten established vaccine protocols, forcing biotech firms to pivot R&D spending toward politically favored alternatives.
